PDCD1 and primary central nervous system lymphoma: In the second case, orelabrutinib, PD-1 inhibitor plus lenalidomide acted as the salvage treatment and achieved another PR after disease progression and then orelabrutinib achieved sustained remission as maintenance treatment, which showed similar response for relapsed/refractory HIV-negative PCNSL cases [16, 17].